Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates
04. August 2022 16:05 ET
|
Sana Biotechnology, Inc
Expect cash runway into 2025, enabling multiple data readouts across platforms for lead programs, driven by significant cash savings from manufacturing facility move to Bothell, Washington as well as...
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates
17. Juni 2022 09:00 ET
|
Sana Biotechnology, Inc
First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune...
Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting
13. Juni 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company will...
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
07. Juni 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory
01. Juni 2022 16:05 ET
|
Sana Biotechnology, Inc
Replacement of Fremont, CA Facility Estimated to Save Over $100M in the Next Three Years Global Cell Therapy Manufacturing Expert Snehal Patel Appointed Head of Manufacturing Veteran Regulatory...
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
12. Mai 2022 17:40 ET
|
Sana Biotechnology, Inc
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice...
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
10. Mai 2022 16:05 ET
|
Sana Biotechnology, Inc
Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allogeneic...
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
04. Mai 2022 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
02. Mai 2022 16:35 ET
|
Sana Biotechnology, Inc
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts...
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
16. März 2022 08:30 ET
|
Sana Biotechnology, Inc
Plans to present data at multiple scientific conferences in 2022 Expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022 2021 year-end cash position of...